News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated
